An oral hypoglycaemic drug used in combination with other oral hypoglycaemics (either metformin or a sulphonylurea) in the treatment of type 2 diabetes mellitus. Rosiglitazone acts by reducing peripheral insulin resistance. Side effects may include gastrointestinal disturbances, weight gain, and anaemia.
Rosiglitazone |
|
|